Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes

Mar 27 2019

• By Derrick Gingery

Pill Production

Related Content

Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen

Dec 12 2017

Benefit-Risk Frameworks May Be Coming To US FDA Advisory Committees

Apr 03 2018

Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb

Jan 18 2018

Complete Response Letters: US FDA Trying To Identify Subsets For Public Release

Jan 17 2018

FDA Reassures Patients Of Generic Drug Quality Amid Questions In Media Analysis

Feb 24 2019

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

Mar 18 2019

Pfizer Must Correct Data Integrity Problems Seen At India Plant Globally, FDA Says

Mar 14 2019

“Emerging Sponsors” Pose Regulatory, Public Relations Challenges For Drug Review Process, FDA’s Jenkins Says

Dec 08 2011

Additional Topics

United States Manufacturing Quality Regulation FDA Legislation Drug Safety BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window